We recently published a list of 10 Best Telehealth Stocks to Buy Now. In this article, we are going to take a look at where Doximity, Inc. (NYSE:DOCS) stands against other best telehealth stocks to buy right now.
According to Grand View Research, the telehealth market size in the US was valued at $42.54 billion in 2024. It is expected to grow at a notable compound annual growth rate of 23.8% between 2025 and 2030. Some of the primary factors supporting this growth include the rising demand for remote healthcare services, large-scale penetration of connected home services, and high internet usage. In addition, the global adoption of smartphones, advancements in technology, and a surge in government initiatives to develop telehealth programs are also supporting market growth.
Since the cost of in-person healthcare provision is increasing in the country, telehealth presents a significant opportunity in the healthcare sector. According to McKinsey, around $250 billion of the present US healthcare spending can be virtualized. This includes training for medical professionals, regular check-in appointments for chronic diseases, psychiatric care, and more, all administered and accessed through each individual’s preferred device.
READ ALSO: 10 Best Mid Cap Biotech Stocks to Buy and 12 Best Diagnostics Stocks to Invest In Right Now.
Some experts view medical, healthcare, and big pharma stocks as immune from trade carnage, making them a safe haven amid the uncertainty brought about by Trump’s tariffs. Since Trump’s tariffs and macroeconomic uncertainties are causing significant market volatility, we discussed the potential of healthcare stocks as a safe haven amidst the ongoing turmoil in a recently published article on the 10 Best Medical Stocks to Buy According to Billionaires. Here is an excerpt from the article:
On April 8, Mizuho Securities America healthcare sector strategist Jared Holz opined that managed care, particularly the government-centric names, are somewhat safe as they are insulated from tariffs as US-based companies. In fact, the economic slowdown is actually beneficial for them as they want less utilization and less patience through the system, which is how they typically beat numbers. He said that managed care is having a good day, and investors might think about owning some companies in the sector.
It is, however, a relative game, as there are several different variables at play, and investors are essentially playing a game of hopscotch in an attempt to jump from one area to another, whether it’s tariffs, drug pricing, or other public policies. He painted a similar picture for medical device stocks that are more US-centric. These two sectors thus have less risk relative to others, making them somewhat of a safe haven.
We sifted through stock screeners, financial media reports, and ETFs to compile a list of 25 telehealth stocks and chose the top 10 most popular among hedge funds as of Q4 2024. The list is ordered in ascending order of hedge fund sentiment. We sourced the hedge fund sentiment data from Insider Monkey’s database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Number of Hedge Fund Holders: 38
Doximity, Inc. (NYSE:DOCS) develops and operates an online platform for medical professionals. Its cloud-based software allows physicians and healthcare professionals to collaborate with their colleagues, conduct virtual patient visits, coordinate patient care, manage their careers, and stay on top of the latest medical news. It offers Hiring, Marketing, and Productivity Solutions to health systems, pharmaceutical manufacturers, medical recruiting firms, and other healthcare companies. Its Productivity Solutions segment comprises on-call scheduling, telehealth, and AI-assisted medical correspondence tools that help clinicians streamline their workflow.
Doximity, Inc. (NYSE:DOCS) anticipates the pharma healthcare professionals (HCP) digital market to grow approximately 5% to 7% and plans to grow ahead of the overall market. Its record engagement and strong competitive standing position it to attain this objective.
The company also reported impressive fiscal Q3 2025 results, resulting in soaring bullish sentiments for the company. Its net income for fiscal Q3 2024 grew 57% year-over-year to $75.2 million, while net profit for the first nine months rose by 50.2% year-over-year to $160.7 million. Revenue for fiscal Q3 2025 also grew by 24.6% year-over-year, reaching $168.6 million. Doximity, Inc. (NYSE:DOCS) expects this momentum to continue and anticipates revenue for the full fiscal year ending March 31, 2025, to settle between $564.6 million and $565.6 million.
Overall, DOCS ranks 7th on our list of the best telehealth stocks to buy right now. While we acknowledge the potential for DOCS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than DOCS but trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.